Welcome to our dedicated page for Azitra SEC filings (Ticker: AZTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Azitra, Inc. (AZTR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, which are central to understanding this clinical stage biopharmaceutical issuer focused on precision dermatology. Through its Forms 8-K, S-1, DEF 14A and related documents, Azitra outlines the status of its live biotherapeutic and engineered protein programs, capital structure, and stock exchange compliance.
Filings such as Form 8-K detail material events, including notices from NYSE American regarding non-compliance with minimum stockholders’ equity requirements and subsequent acceptance of Azitra’s plan to regain compliance by April 1, 2027. Other 8-K reports describe private placement transactions involving common stock, pre-funded warrants, and common stock purchase warrants, as well as placement agency agreements and registration rights agreements tied to these financings. Additional 8-Ks furnish quarterly financial results and discuss reverse stock split actions implemented through amendments to the company’s certificate of incorporation.
Azitra’s Form S-1 registration statements provide further insight into its equity line of credit with Alumni Capital LP, the potential issuance of ELOC shares and warrants, and the resale registration of securities issued in private transactions. These documents explain how the company may raise capital over time and the number and types of securities that may be issued. The DEF 14A definitive proxy statement for a Special Meeting of Stockholders describes proposals to approve share issuances under NYSE American rules, including shares underlying warrants issued pursuant to a securities purchase agreement.
On this page, Stock Titan pairs Azitra’s real-time EDGAR filings feed with AI-powered summaries that help explain the significance of key documents. Users can quickly understand stock issuance proposals, listing standard issues, reverse stock splits, and financing structures without reading every page of each filing. Access to forms related to insider or major holder transactions, when filed, complements this view by showing how ownership and capital structure evolve as Azitra advances its ATR-12, ATR-04, and ATR-01 programs.
Azitra held its 2025 annual meeting on June 23, where stockholders voted on several key proposals. Three out of four proposals were concluded, while one remains pending:
- Board Elections: All four director nominees were successfully elected: Francisco D. Salva, Travis Whitfill, Barbara Ryan, and John Schroer, with each receiving over 1 million votes in favor
- Auditor Appointment: Stockholders ratified Grassi & Co., CPAs as the independent auditor for FY2025, with 8.37 million votes in favor
- Share Issuance: Approved issuance of >19.99% of outstanding common stock under purchase agreement with Alumni Capital LP, receiving 1.2 million favorable votes
- Pending Vote: Proposal to increase authorized common stock from 100M to 200M shares was adjourned to July 3, 2025, allowing additional time for stockholder voting
The company maintains its status as an emerging growth company and trades on NYSE American under symbol AZTR.
Azitra has filed a significant update regarding their 2025 Annual Meeting of Stockholders scheduled for June 23, 2025. The company has issued a supplement to their previously filed proxy statement, specifically addressing changes to the voting standard for Proposal 2.
The key proposal under consideration seeks stockholder approval to double the authorized common stock from 100,000,000 to 200,000,000 shares. This represents a material change to the company's capital structure that could significantly impact existing shareholders.
Key details:
- Annual Meeting to be held virtually on June 23, 2025, at 11:00 AM ET
- Original proxy statement filed May 29, 2025
- Supplementary proxy statement filed June 18, 2025
- Company maintains emerging growth company status
Stockholders are encouraged to review the complete proxy materials available on the SEC website before making voting decisions.
Azitra has filed a supplementary proxy statement (DEFA14A) to update voting requirements for their upcoming Annual Meeting on June 23, 2025. The key modification relates to Proposal 2, which seeks to increase authorized common stock from 100 million to 200 million shares.
Due to recent Delaware General Corporation Law amendments (Section 242(d)(2)), the voting standard has changed. The proposal now requires a majority of votes cast rather than a majority of outstanding shares. Key voting details:
- Abstentions will not count as votes "For" or "Against"
- Brokers have no discretionary voting authority
- Broker non-votes won't be counted as votes cast
Previously submitted proxies remain valid unless revoked. The Board unanimously recommends voting "FOR" all proposals. Shareholders can vote via Internet, telephone, or mail, and can change their votes through various methods including attending the virtual meeting on June 23, 2025.